Johnson & Johnson Down Over 4% After Seeking Drug Approval -- Data Talk

Johnson & Johnson (JNJ) is currently at $134.01, down $6.10 or 4.35%

-- Would be lowest close since June 4, 2019, when it closed at $133.73

-- On pace for largest percent decrease since Dec. 14, 2018, when it fell 10.04%

-- Earlier Friday, The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) said it submitted an application with the U.S. Food and Drug Administration seeking approval of its new subcutaneous formulation of Darzalex, or daratumumab, for certain patients with multiple myeloma

-- Credit Suisse initiated Johnson & Johnson at outperform with a price target of $156.00/share, Benzinga reported

-- Currently down three consecutive days; down 5.23% over this period

-- Worst three day stretch since the three days ending May 29, 2019, when it fell 6.05%

-- Down 3.78% month-to-date

-- Up 3.84% year-to-date

-- Down 9.54% from its all-time closing high of $148.14 on Jan. 22, 2018

-- Up 6.42% from 52 weeks ago (July 13, 2018), when it closed at $125.93

-- Down 9.35% from its 52 week closing high of $147.84 on Dec. 13, 2018

-- Up 9.09% from its 52 week closing low of $122.84 on Dec. 24, 2018

-- Traded as low as $132.97; lowest intraday level since June 4, 2019, when it hit $132.58

-- Down 5.1% at today's intraday low; largest intraday percent decrease since May 29, 2019, when it fell as much as 6.24%

-- Worst performer in the DJIA today